Healthcare Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare
SECTOR
Life Sciences

RELEASE DATE
23-Aug-2022
REGION
North America
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
PD7A-01-00-00-00
SKU
HC03576-GL-MR_26831
Yes
SHARE

Frost Radar™: US Liquid Biopsy, 2022
Published on: 23-Aug-2022 | SKU: HC03576-GL-MR_26831

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comprehensive multi-cancer tests with companion diagnostic claims received approval in late 2020. Driven by multiple FDA liquid biopsy approvals in 2021, the ability to diagnose a tumor and monitor its progression and treatment response without performing a tissue biopsy is one of the most groundbreaking advancements in the In vitro diagnostics (IVD) market. In a field of more than 35 US industry participants, Frost & Sullivan independently plotted the top 9 Liquid Biopsy companies in this Frost Radar™ analysis: GRAIL, Exact Sciences Corp., Roche Foundation Medicine, Guardant Health, Natera, Inc., Helio Genomics (formerly Helio Health, Helio), Freenome, Quanterix, and Tempus, Inc., that are truly innovating and best positioned to deliver high value to customers in the future.

Author: Amartya Bose

Strategic Imperative

Growth Environment

Frost Radar™: US Liquid Biopsy Market

Frost Radar™: Competitive Environment

Frost Radar™: Competitive Environment (continued)

GRAIL

Exact Sciences Corp

Roche Foundation Medicine

Guardant Health

Natera, Inc.

Helio Genomics

Quanterix Corp

Freenome

Tempus, Inc.

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Life Sciences research

13 Jan 2025   |   Global   |   Market Outlook

Top 6 Growth Opportunities for the Digital Health Industry, 2025

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...

17 Dec 2024   |   Global   |   Market Research

Cybersecurity in Healthcare, United States, 2024

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...

12 Dec 2024   |   Global   |   Market Outlook

Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...

05 Dec 2024   |   Global   |   Frost Radar

Frost Radar™: Enterprise Conversational AI in Healthcare, 2024

This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...

27 Nov 2024   |   Global   |   Market Research

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comprehensive multi-cancer tests with companion diagnostic claims received approval in late 2020. Driven by multiple FDA liquid biopsy approvals in 2021, the ability to diagnose a tumor and monitor its progression and treatment response without performing a tissue biopsy is one of the most groundbreaking advancements in the In vitro diagnostics (IVD) market. In a field of more than 35 US industry participants, Frost & Sullivan independently plotted the top 9 Liquid Biopsy companies in this Frost Radar™ analysis: GRAIL, Exact Sciences Corp., Roche Foundation Medicine, Guardant Health, Natera, Inc., Helio Genomics (formerly Helio Health, Helio), Freenome, Quanterix, and Tempus, Inc., that are truly innovating and best positioned to deliver high value to customers in the future. Author: Amartya Bose
More Information
Deliverable Type Frost Radar
Author Amartya Bose
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Liquid Biopsy Market 2022
Keyword 2 US Liquid Biopsy Market
Keyword 3 In vitro diagnostics (IVD) market
Podcast No
WIP Number PD7A-01-00-00-00

Frost Radar™: US Liquid Biopsy, 2022

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03576-GL-MR_26831